About ProteinSimple
ProteinSimple is a company based in San Jose (United States) founded in 2004 was acquired by Bio-Techne in June 2014. ProteinSimple has raised $114.29 million across 8 funding rounds from investors including Royal Bank of Canada, Bio-Techne and Wellcome. ProteinSimple has completed 4 acquisitions, including Alpha Innotech, Brightwell Tech and Convergent Bioscience. ProteinSimple operates in a competitive market with competitors including Somalogic, Cyrus Biotechnology, Vividion Therapeutics, Nautilus Biotechnology and Amunix, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bio-Techne Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$114.29 M (USD)
in 8 rounds
-
Latest Funding Round
$13 M (USD), Series F
May 11, 2011
-
Investors
Royal Bank of Canada
& 10 more
-
Employee Count
Not available
-
Investments & Acquisitions
Alpha Innotech
& 3 more
-
Acquired by
Bio-Techne
(Jun 17, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ProteinSimple
Unlock access to complete
Software Development Team
92 people
Sales and Marketing
76 people
Leadership Team
40 people
Product Management Team
35 people
Senior Team
31 people
Finance and Accounting
20 people
Human Resources and Administration
18 people
Advanced Team
13 people
Unlock access to complete
Funding Insights of ProteinSimple
ProteinSimple has successfully raised a total of $114.29M across 8 strategic funding rounds. The most recent funding activity was a Series F round of $13 million completed in May 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ProteinSimple
ProteinSimple has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Royal Bank of Canada, Bio-Techne and Wellcome.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Early-stage healthcare startups are supported with venture capital.
|
Locked | Locked | Locked | |
|
Investments in early and late-stage US companies are made.
|
Locked | Locked | Locked |
Investor details for ProteinSimple
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ProteinSimple
ProteinSimple has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Alpha Innotech, Brightwell Tech and Convergent Bioscience.
Investment portfolio details for ProteinSimple
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Protein fractionation instruments and software for mass spectrometry are developed.
|
Locked | Locked | 2002 | Locked | |
|
Tech solutions are explored via a dedicated blog platform.
|
Locked | Locked | 2001 | Locked | |
|
Protein characterization equipment is supplied for pharmaceutical and biotech sectors.
|
Locked | Locked | 1995 | Locked |
Complete acquisition details for ProteinSimple
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ProteinSimple
Detailed financials for ProteinSimple
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proteinsimple Comparisons
Peer comparison for ProteinSimple
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ProteinSimple
ProteinSimple operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Cyrus Biotechnology, Vividion Therapeutics, Nautilus Biotechnology and Amunix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
Detailed competitors of ProteinSimple
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proteinsimple
Complete news archive for ProteinSimple
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProteinSimple
ProteinSimple was founded in 2004 and raised its 1st funding round 2 years after it was founded.
ProteinSimple is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
ProteinSimple is a funded company, having raised a total of $114.29M across 8 funding rounds to date.
Provider tools to help researchers with protein analysis. It offers Simple Plex Assays, multi-analyte immunoassays for biomarker research, Micro-Flow Imaging (MFI), a solution for aggregate and particle analysis, as well as monitoring and characterizing aggregates during the formulation development process, and AlphaImager gel documentation systems that provide imaging for a range of UV fluorescent and colorimetric applications. The company also provides Simple Western Assays that provide quantitative protein characterization and protein analysis in precious samples and an iCE System that measures protein purity, charges heterogeneity protein analysis, evaluates formulation development, and screens cell lines.
ProteinSimple's top competitors include Somalogic, Vividion Therapeutics and Cyrus Biotechnology.
ProteinSimple has made 4 acquisitions, including Alpha Innotech, Brightwell Tech, and Convergent Bioscience.
ProteinSimple has 11 investors. Key investors include Royal Bank of Canada, Bio-Techne, Wellcome, Wellcome, and Domain Associates.